Advertisement

Predictive Markers and Targeted Therapies in Thyroid Cancer and Selected Endocrine Tumors

  • Juan C. Hernandez-Prera
  • Bruce M. Wenig
Chapter

Abstract

Endocrine tumors are ubiquitous and can arise in many organs such as the pituitary, the pancreas, the ovaries, the testicles, the thyroid, the parathyroid, and the adrenal glands. Many of these tumors retain the ability to secrete hormones which can be the source of their symptomatology. In this chapter, we will mainly cover biomarkers associated with thyroid cancer – the most common malignancy of the endocrine system – and briefly touch upon other tumors such as the parathyroid carcinoma and adrenal gland neoplasia.

Keywords

Papillary thyroid carcinoma Follicular thyroid carcinoma Mitogen-activated protein kinase (MAPK) signaling pathway PI3K/Akt/mTOR signaling pathway Tyrosine kinase inhibitors Adrenocortical carcinoma Parathyroid carcinoma Pheochromocytoma Paraganglioma 

Notes

Acknowledgment

We would like to thank Dr. Janis de la Iglesia from the Department of Head and Neck/Endocrine Cancer at Moffitt Cancer Center for creating Fig. 45.1 of this chapter.

Suggested Readings

  1. 1.
    Angelousi A, et al. Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies. Endocr Relat Cancer. 2017;24(6):R239–59.CrossRefPubMedGoogle Scholar
  2. 2.
    Brose MS, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–28.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676–90.CrossRefGoogle Scholar
  4. 4.
    Elisei R, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–46.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Erovic B, et al. Biomarkers of parathyroid carcinoma. Endocr Pathol. 2012;23:221.CrossRefPubMedGoogle Scholar
  6. 6.
    Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054–67.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Fassnacht M, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16:426–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Fishbein L, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31(2):181–93.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Haugen BR, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Mete O, et al. Immunohistochemical biomarkers of adrenal cortical neoplasms. Endocr Pathol. 2018;  https://doi.org/10.1007/s12022-018-9525-8. [Epub ahead of print].CrossRefPubMedGoogle Scholar
  11. 11.
    Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011;135(5):569–77.PubMedGoogle Scholar
  12. 12.
    Schlumberger M, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Viola D, et al. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience. Endocr Relat Cancer. 2016;23(4):R185–205.CrossRefPubMedGoogle Scholar
  14. 14.
    Wells SA Jr, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the American Thyroid Association Guidelines Task Force on medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Wells SA Jr, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2011;30(2):134–41.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Zheng S, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;30(2):363.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Anatomic PathologyMoffitt Cancer Center, University of South FloridaTampaUSA

Personalised recommendations